Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Opens Floor For Debate Of Off-Label Claims, First Amendment Issues

This article was originally published in The Gray Sheet

Executive Summary

FDA's request for comments on First Amendment issues creates a forum for stakeholders to submit comments on FDA's policy regarding off-label claims

You may also be interested in...



FDA Approps Amendment Targets Chief Counsel Troy

FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts

FDA Approps Amendment Targets Chief Counsel Troy

FDA Chief Counsel Daniel Troy's intervention in civil suits on behalf of device maker Pacesetter and several drug firms has drawn a rebuke from House legislators in the form of funding cuts

FDA First Amendment Plan: Series Of Guidances Rather Than Omnibus Rule

FDA's policy on regulating commercial speech will be addressed through a series of guidances and rules related to specific areas of interest

Related Content

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel